Richter's Transformation

15 clinical trials · Condition

Record	Firm	Date
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (NCT05294731)	BeiGene	2022-05-06
Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT04806035)	TG Therapeutics, Inc.	2021-04-28
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas (NCT04305444)	Zhejiang DTRM Biopharma	2020-04-24
Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma (NCT03778073)	TG Therapeutics, Inc.	2019-04-17
Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation (NCT03153514)	German CLL Study Group	2017-11-13
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (NCT03162536)	ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)	2017-06-26
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation (NCT03121534)	M.D. Anderson Cancer Center	2017-06-22
PNT2258 for Treatment of Patients With Richter's Transformation (Brighton) (NCT02378038)	Sierra Oncology LLC - a GSK company	2015-08-01
Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation (NCT02138786)	Karyopharm Therapeutics Inc	2014-11-14
Registry of the German CLL Study Group (NCT02863692)	German CLL Study Group	2013-08-01
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL (NCT01217749)	Pharmacyclics LLC.	2010-12-01
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias (NCT00472849)	M.D. Anderson Cancer Center	2007-05-01

Track Richter's Transformation automatically

Every clearance here is in the API, with alerts when new ones post.